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inactive periods gave rise to no change in the time spent 
in the wakefulness, REM, and NREM sleep compared with 
control. The results indicated that VTA neurons activated 
pharmacogentically played important roles in promoting 
wakefulness.
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Introduction
The ventral tegmental area (VTA) contains dopamine (DA) 
containing neurons and is traversed by many blood ves-
sels and nerve fibers. Close to its poorly defined borders 
are found DA and 5-HT containing neurons [1]. The VTA 
comprises several subdivisions and neurons synthesizing 
neurotransmitters, such as DA, GABA, or glutamate [2]. 
The DA neurons arises in the VTA and projects to: (1) the 
septal area, olfactory tubercle, nucleus accumbens, amyg-
daloid complex, and piriform cortex (mesolimbic projec-
tion) and (2) the medial prefrontal, cingulate, and entorhi-
nal areas (mesocortical projection) [1]. The VTA is crucial 
for brain functions, such as voluntary movement and goal-
directed behavior, as well as cognition, emotion, reward, 
working memory, and decision making [3–6].
Accordingly, DA midbrain system dysfunction is asso-
ciated with neurologic and psychiatric diseases, such as 
schizophrenia, addiction, attention deficit hyperactivity dis-
order, and Parkinson’s disease [7]. Several lines of evidence 
suggest that DA signals are closely associated with regu-
lation of sleep-wake activity [8, 9]. In humans, malfunc-
tion of the brain DA system is associated with neuropsy-
chopathy, with disruption of sleep as one symptom [10]. 
Systemic administration of a selective  D1 receptor agonist 
Abstract The ventral tegmental area (VTA) is crucial 
for brain functions, such as voluntary movement and cog-
nition; however, the role of VTA in sleep-wake regulation 
when directly activated or inhibited remains unknown. In 
this study, we investigated the effects of activation or inhi-
bition of VTA neurons on sleep-wake behavior using the 
pharmacogenetic “designer receptors exclusively acti-
vated by designer drugs (DREADD)” approach. Immu-
nohistochemistry staining was performed to confirm the 
microinjection sites, and combined with electrophysi-
ological experiments, to determine whether the VTA neu-
rons were activated or inhibited. The hM3Dq-expressing 
VTA neurons were excited confirmed by clozapine-N-
oxide (CNO)-driven c-Fos expression and firing in patch-
clamp recordings; whereas the hM4Di-expressing VTA 
neurons inhibited by reduction of firing. Compared with 
controls, the activation of VTA neurons at 9:00 (inactive 
period) produced a 120.1% increase in the total wakeful-
ness amount for 5 h, whereas NREM and REM sleep were 
decreased by 62.5 and 92.2%, respectively. Similarly, when 
VTA neurons were excited at 21:00 (active period), the 
total wakefulness amount increased 81.5%, while NREM 
and REM sleep decreased 64.6 and 93.8%, respectively, for 
8 h. No difference of the amount and EEG power density of 
the NREM sleep was observed following the arousal effects 
of CNO. The inhibition of VTA neurons during active or 
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induced an increase of wakefulness (W) and a reduction 
of slow wave sleep (SWS) and REM sleep. On the other 
hand, low doses of  D2 receptor agonist reduced W and 
increased SWS and REM, whereas large doses induced the 
opposite effect [11]. Psycho-stimulants promote wakeful-
ness by inhibiting the DA reuptake transporter (DAT) and 
thereby enhancing the extracellular DA levels in mice [12]. 
The results are often controversial by drug effects on tar-
gets outside the VTA area or by potential disruption of neu-
ral circuits during development after gene knockout. The 
effects of activation or inhibition of VTA neurons on sleep/
wake behavior remains to be directly tested.
The VTA is a heterogeneous area where dopaminergic 
and non-dopaminergic neurons are intermixed [2]. The 
pharmacogenetic technique “designer receptors exclu-
sively activated by a designer drug” DREADD [13] utilizes 
extrinsic muscarinic receptors (hM3Dq for excitation and 
hM4Di for inhibition) that have lost their affinity for endog-
enous acetylcholine but can still be activated by a synthetic 
inert ligand (clozapine-N-oxide [CNO]). Activation of 
Gq-coupled hM3Dq by CNO has previously been shown 
to activate neurons through a phospholipase C-dependent 
mechanism [14]. CNO can also stimulate the Gi/o-coupled 
hM4Di receptor, thereby activating the inwardly rectifying 
potassium 3 channel, resulting in membrane hyperpolariza-
tion and neuronal silencing [13]. In this way, the activity of 
VTA neurons can be manipulated temporarily and revers-
ibly. Our study established a direct link between the activ-
ity of midbrain VTA neurons and arousal promotion. The 
results will contribute for understanding the roles of the 
VTA area in regulation of sleep and wake states, which will 




Pathogen-free adult male S129 mice (25–30  g) were 
obtained from the Laboratory Animal Center of Chinese 
Academy of Sciences (Shanghai, China). The animals 
were housed in individual cages at a constant tempera-
ture (24 ± 1 °C) with a relative humidity (60 ± 2%) on an 
automatically controlled 12:12 light/dark cycle (lights on 
at 7:00). The mice had free access to food and water. The 
experimental protocols were approved by the Commit-
tee on the Ethics of Animal Experiments of the University 
of Fudan, Shanghai Medical College (Shanghai, China). 
Every effort was made to minimize the number of ani-




Male mice were anesthetized with chloral hydrate (5% in 
saline [360  mg/kg]), then placed in a stereotaxic frame, 
so that the head was fixed. A burr hole was made, and a 
fine glass pipette (1  mm glass stock, tapering slowly to a 
10–20  μm tip) containing adeno-associated viral (AAV) 
was bilaterally lowered to the VTA (coordinates rela-
tive to bregma:  anterioposterior = − 3.4  mm, mediolat-
eral = ± 0.3  mm, dorsoventral = −4.0  mm) [15]. Then, the 
AAV vectors (0.05 µl per side) were injected with nitrogen 
gas pulses. After ten additional min, the pipette was slowly 
withdrawn. In our study, we employed an evolved G-pro-
tein-coupled muscarinic receptor (hM3Dq or hM4Di) that 
is selectively activated or inhibited by the exogenous ligand 
CNO. The animals recovered for 2 weeks before electrodes 
were implanted for electroencephalogram (EEG) and elec-
tromyogram (EMG) recordings.
Sleep recording and vigilance state analysis
To monitor EEG signals, two stainless steel screws were 
positioned 1  mm anterior to the bregma, both of which 
were 1.5  mm laterals to the midline [15]. Two Teflon-
coated, stainless steel wires were placed into the trapezius 
muscles bilaterally for EMG recording. All electrodes were 
attached to a micro-connector and fixed to the skull with 
dental cement. After surgery, each mouse was allowed 
recover for 1 week before polygraphic recording. The 
recordings were started at 7:00 (onset of light period) or 
19:00 (onset of dark period). We recorded EEG and EMG 
for two consecutive days. On day 1, the mice were treated 
with vehicle (intrape ritoneal [i.p.] saline) at 9:00 or 21:00, 
and the recordings served as the baseline data. On the next 
day, CNO (1 mg/kg) was injected at the same time on day 
1. The same mice were used four times for different injec-
tion time and drug (9:00 saline/CNO; 21:00 saline/CNO). 
The interval for each experiment was 2 days.
The EEG and EMG signals were amplified and filtered 
(EEG, 0.5–30  Hz; EMG, 20–200  Hz), then digitized at a 
sampling rate of 128  Hz and recorded by VitalRecorder 
(Kissei Comtec, Nagano, Japan) [16]. Vigilant states were 
automatically classified off-line under 10-s epochs into 
three stages, i.e., wakefulness, rapid eye movement (REM), 
and non-rapid eye movement (NREM) sleep, using SLEEP-
SIGN (Kissei Comtec) according to standard criteria [17]. 
Wakefulness is defined by a low-amplitude and high-fre-
quency EEG with a high activity of EMG. REM sleep is 
characterized by a low-amplitude, high-frequency EEG 
associated with the absence of EMG activity; the presence 
of EEG theta-activity (6–9 Hz) in the recording can be used 
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to confirm this state. NREM sleep is commonly defined by 
a high-amplified EEG associated with a low-voltage EMG. 
The presence of high EEG delta activity (0.65–4 Hz) is also 
employed to characterize this state. As a final step, defined 
sleep-wake stages were examined visually and corrected if 
necessary [18].
Drugs and administration
CNO (LKT Labs C4759, USA) was dissolved in saline 
to a concentration of 1  mg/10  ml before treatment. CNO 
was administered by i.p.to each mouse (0.1 ml/10 g body 
weight).
Immunohistochemistry
One group of mice was injected with saline and the other 
with CNO at a dose of 1 mg/kg. Two hours later, the ani-
mals were deeply anesthetized with 5% chloral hydrate 
(360  mg/kg) and were immediately perfused transcardi-
ally with 60  ml of saline, followed by 50  ml of ice-cold 
4% paraformaldehyde (PFA). The brains were removed 
and post-fixed for 24  h at 4 °C in 4% PFA, then equili-
brated in phosphate buffer containing 30% sucrose at 4 °C. 
Coronal Sect. (30 μm) were cut serially on a cryostat. For 
double immunohistochemistry analysis, sections were 
thrice washed with phosphate-buffered saline (PBS) and 
incubated with 0.3% hydrogen peroxide in 0.1 M PBS for 
30  min. After washing in PBS, the sections were incu-
bated with a primary rabbit anti-c-Fos (1:10000, Millipore 
2239640, USA) antibody diluted in PBS containing 0.3% 
Triton X-100 (PBST) for 48 h. On the second day, the sec-
tions were rinsed and incubated in biotinylated anti-rabbit 
secondary antiserum (1:1000, Jackson ImmunoResearch 
BA-100, West Grove, PA, USA) for 2 h. After thrice wash-
ing in PBS, all sections were then treated with avidin-bio-
tin-peroxidase complex (1:1:1000, Vectastain ABC Elite 
kit; Vector Laboratories PK-6100, San Francisio, CA, 
USA) for 90  min. The peroxidase reactions were visual-
ized with 0.05% 3, 3- diamino-benzidine (DAB; Sigma 
SK-4100, St. Louis, MO, USA) in 0.1  M PB and 0.01% 
hydrogen peroxide. After three washes in PBS, the sec-
tions were incubated in another primary rabbit anti-DsRed 
(1:10000, Takara 632496, USA) antibody diluted in PBST 
overnight. The procedure was similar as c-Fos staining pre-
viously described above with the exception of the last step; 
the color reagents of DAB did not include nickel. All sec-
tions were mounted onto gelatin-coated slides, dehydrated 
in graded ethanol, placed into xylene, and cover-slipped.
The sections were examined under bright-field illumi-
nation with a microscope (Leica Microsystems, Wetzlar, 
Germany). Using light microscopy, neurons positive for 
c-Fos were identified by dense black nuclear staining; the 
mCherry were identified by brown cytomembrane stain-
ing. Locations in the brain were confirmed by staining 




Electrophysiologic experiments were performed on slices 
retrieved from the mice injected with virus 3 weeks ear-
lier. Briefly, the mice were sacrificed by decapitation, 
and the VTA and SNc were identified according to stere-
otaxic coordinates [15]. Coronal midbrain slices (300  μm 
thick) containing VTA and SNc were cut using a vitratome 
(Leica VT 1000  S, USA) in ice-cold glycerol-based arti-
ficial cerebrospinal fluid containing: glycerol (260  mM), 
KCL  (5  mM),  KH2PO4 (1.25  mM),  MgSO4 (1.3  mM), 
 CaCL2 (0.5 mM),  NaHCO3(20 mM) and glucose (10 mM), 
and saturated with 95%  O2–5%  CO2. Slices were allowed to 
recover for at least 1 h in a holding chamber at a water bath 
(32 °C) before recording.
Patch‑clamp recordings in the whole‑cell configuration
This recording configuration was used to study the effects 
of CNO application on a single VTA/SNc cell. The path 
electrodes were pulled from borosilicate glass capillar-
ies (1.5 mm outside diameter, 0.86 inside diameter, Sutter 
Instrument, Novato, CA) on a Brown-Flaming micropipette 
(Model P-97, Sutter Instrument, Novato, CA, USA). The 
path electrode had a resistance of 4–6 MΩ when filled with 
pipette solution containing potassium gluconate (120 mM), 
KCl (20 mM), MgCl2 (1 mM), CaCl2 (0.16 mM), HEPES 
(10 mM), EGTA (0.5 mM), MgATP (2 mM), and NaGTP 
(0.5 mM); with the pH was adjusted to 7.4 with KOH. A 
single coronal slice was transferred to the recording cham-
ber, where the slice was held down with a platinum ring. 
Artificial cerebrospinal fluid (ACSF) gassed with 95% 
 O2–5%  CO2 flowed through the bath (2  ml/min). VTA/
SNc neurons were identified under visual guidance using 
upright microscope (BX-51, Olympus, Japan) with a 40× 
water immersion objective lens. The cells were recorded 
using mCherry fluorescent signals. The image was detected 
with a CCD camera (U-TV1X-2, Olympus, Japan) and dis-
played on a monitor. The mCherry-positive neurons were 
clamped to record spontaneous action potentials and/or 
membrane potentials. The series resistance (3–5 MΩ) and 
input resistance (300–400 MΩ) were monitored throughout 
the cell recording, and data were discarded when either of 
the two resistances changed by >20% [19].
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Statistical analysis
All data were presented as the mean ± standard error. Histo-
grams of the amounts of sleep and wakefulness after vehi-
cle or CNO injection were compared using a Student’s two-
tailed paired t test. The hourly amounts of each stage for 
sleep–wake profiles in mice treated with vehicle or CNO 
were compared using repeated-measures analysis of vari-
ance followed by Fisher’s probable least-squares difference 
(PLSD) test, p < 0.05 was considered statically significant.
Results
Injection sites confirmed by mCherry expression 
of AAV
To control the VTA neurons in behaving animals, 
we bilaterally injected the AAV containing excita-
tory (hSyn-hM3Dq-mCherry-AAV10) or inhibitory 
(hSyn-hM4Di-mCherry-AAV10) modified muscarinic 
G-protein-coupled receptors which can be activated by 
CNO into the VTA (Fig.  1AB). AAV vectors without 
hM3Dq or hM4Di receptors (hSyn-mCherry-AAV10) 
were used as control (Fig.  1Cc). Robust cell-surface 
expression of the hM3Dq (Fig. 1Dd) or hM4Dq receptors 
(Fig. 1Ee) was observed in the VTA.
Modulation of the activities of VTA neurons by CNO
CNO was given by i.p. with minimal perturbation. The 
effects of excitatory hM3Dq and inhibitory hM4Di were 
examined during both the light and dark periods. After 
EEG/EMG recording, following treatment of CNO or 
saline in mice expressing mCherry, hM3Dq, or hM4Di, 
Fig. 1  Expression of the mCherry, hM3Dq-mCherry, or hM4Di-
mCherry in VTA. A Schematic representation of AAV vector micro-
injected. ITR, inverted terminal repeat; hSyn, human synapsin 
promoter; WPRE, woodchuck hepatitis virus post-transcriptional 
regulatory element. B Red colored sites in coronal section show the 
injection target in mice. C, D, E Coronal brain sections at the level 
of VTA prepared from mice expressing mCherry, hM3Dq-mCherry, 
or hM4Di-mCherry following hSyn-mCherry-AAV10 (C), hSyn-
hM3Dq-AAV10 (D), and hSyn-hM4Di -AAV10 (E) microinjection. “c, 
d, e” higher magnification of the square region indicated in “A, B, C”. 
Scale bars = 100 μm (C, D, E); 50 μm (c, d, e)
Fig. 2  Activation or inhibition of VTA neurons by DREADD dem-
onstrated by double staining of c-Fos and mCherry expression. a, c 
Only small numbers of c-Fos- immunoreactive nuclei were observed 
in mCherry-positive neurons after saline or CNO administration in 
mice microinjected with hSyn-mCherry-AAV10 (a) and hSyn-hM4Di-
mCherry-AAV10 (c). b Double expression of c-Fos and mCherry 
(red arrows) induced by CNO was higher than that by saline in mice 
microinjected with hSyn-hM3Dq-mCherry-  AAV10. Inset, high 
power view. Scale bars = 100  μm; inset scales bars = 50  μm. d, e 
Whole-cell current clamp recording showed that bath application of 
CNO (horizontal bar) produced vigorous firing of action potentials 
from hM3Dq/mCherry neurons (n = 6) (d) but inhibited firing from 
hM4Di/mCherry neurons (n = 6) (e) in the VTA. VTA ventral tegmen-
tal area, ml medial lemniscus, IPn interpeduncular nucleus
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Fig. 3  Effects of modulation of VTA neurons’ activity by DREADD 
during light period on vigilant states of mice. a–c Hourly amount 
of wakefulness, REM, and NREM sleep after CNO administration 
in the mice microinjected with hSyn-mCherry-AAV10 (n = 6) (a), 
hSyn-hM3Dq-AAV10 (n = 6) (b), and hSyn- hM4Di -AAV10 (n = 5) 
(c) into the VTA. Each circle represents the hourly mean ± SEM of 
each stage. The horizontal open and filled bars on the X-axes indi-
cate the 12  h light and 12  h dark period, respectively. d–g In mice 
microinjected with hSyn-hM3Dq-AAV10, examples of polygraphic 
recording and corresponding hypnogram after treatment with saline 
(d) and CNO (e); time spent in each stage in 5  h (9:00–14:00) fol-
lowing saline or CNO injection (f); amount and EEG power density 
of NREM sleep in 5 h (14:00–19:00) following CNO-induced arousal 
(g). *p < 0.05, **p < 0.01, assessed by two-tailed paired Student’s t 
test
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the animals were sacrificed and fixed 2 h later for stain-
ing. The VTA slices of these mice were examined by 
double staining with anti-mCherry and anti-Fos antibod-
ies to assess the activity of these VTA neurons.
In wild-type mice with control AAV (hSyn-mCherry-
AAV10) microinjection, in which VTA neurons did not 
express hM3Dq or hM4Di, the double-labeled neurons 
(mCherry-positive neurons with c-Fos-positive nuclei) 
were not seen (Fig. 2a). There was an apparent increase in 
the number of double-labeled neurons in the mice micro-
injected with hSyn-hM3Dq-AAV10 (Fig.  2b). Because the 
neuron activity was inhibited by hM4Di, the mice micro-
injected with hSyn-hM4Di-AAV10 showed no expression 
of the double-labeled neurons (Fig. 2c). Then, we carried 
out target recordings from hM3Dq/mCherry or hM4Di/
mCherry neurons in brain slices to determine the effects of 
CNO on VTA neurons.
Whole-cell current–clamp recordings demonstrated that 
CNO (5 μmol/l) elicited vigorous firing of action potentials 
(Fig.  2d) in hM3Di/mCherry-positive neurons, but inhib-
ited firing of VTA hM4Di/mCherry neurons (Fig. 2e).
Modulation of activities of VTA neurons altered 
behavioral states in mice
After confirming the effectiveness of the pharmacogenetic 
approach, we tested whether or not the selective activa-
tion or inhibition of VTA neurons affects sleep-wake 
states. When CNO was given at 9:00 or 21:00, the amount 
of wakefulness, REM, and NREM sleep in mice microin-
jected hSyn-mCherry-AAV10 or hSyn-hM4Di-AAV10 did 
not change compared with the control group (Figs.  3a, c, 
4a, c).
However, the mice microinjected with hSyn-hM3Dq- 
 AAV10 showed a remarkable increase in wakefulness 
accompanied by reduction in REM and NREM sleep after 
CNO administration (Fig.  3b, d, e). The sum of wake-
fulness in 5  h following CNO injection on light period 
increased 144.9% (174.2 ± 3.1 versus 71.1 ± 8.9  min, 
p < 0.01); meanwhile, the sum of REM sleep decreased 
100% (0 versus 13.9 ± 1.5 min, p < 0.01), and NREM sleep 
decreased 94.0% (5.8 ± 3.1 versus 94.8 ± 7.9 min, p < 0.01) 
(Fig.  3f). When CNO was administered at 21:00 (active 
period), a similar phenomenon was noted in the mice 
microinjected with hSyn-hM3Dq-  AAV10 as the wakeful-
ness increased, while REM and NREM sleep decreased 
(Fig.  4b, d, e). The sum of wakefulness in 8  h follow-
ing CNO injection increased 81.5% (396.3 ± 16.8 versus 
218.4 ± 12.4  min, p < 0.01), meanwhile, the sum of REM 
sleep decreased 93.8% (1.9 ± 0.9 versus 30.8 ± 2.4  min, 
p < 0.01) and NREM sleep decreased 64.6% (81.8 ± 16.3 
versus 230.9 ± 10.4 min, p < 0.01) (Fig. 4f).
Next, we analyze the EEG power density of NREM 
sleep after the VTA neurons’ activities were modified. In 
the mice microinjected with AAV-hM4Di or AAV- con-
trol, EEG power density of NREM sleep did not change 
(data were not shown). As for the hM3Dq positive mice, 
although the activation of the VTA neurons by CNO injec-
tion at 9:00 (Fig. 3g) or 21:00 (Fig. 4g) increased remark-
able wakefulness, but no difference of the amount and EEG 
power density of the NREM sleep was observed during the 
time period following the arousal effects of CNO.
Discussion
The first occurrence of the VTA in the literature is due to 
Tsai in 1925 [20]. In its description of the opossum brain, 
he identified with Nissl and Golgi staining a region lateral 
to the interpeduncular nucleus as the trigonum interpe-
duncular. Recently, the VTA DA neurons were thought to 
be homogeneous in their properties and behavioral func-
tions, such that they express characteristic phasic excitatory 
responses to rewards and cue that predict rewards while 
being inhibited by omission of rewards [21]. A prior study 
wherein the catecholamine-containing neurons in mesen-
cephalon were given electrolytic lesion in cats and the ani-
mals had an obvious decrease in behavioral waking indi-
cated the catecholamine-containing neurons played a role 
in sleep/wake regulation [22]. However, this method pro-
duced irreversible death of neurons and may also lead to 
some compensatory reactions of other brain areas. Despite 
higher dopamine levels usually associated with arousal 
[12, 23], the previous studies did not establish a direct link 
between the activity of VTA neurons and wakefulness.
In the present study, we applied DREADD to pharmaco-
genetically manipulate the activity of VTA neurons. DRE-
ADD utilizes G-protein-coupled receptor signaling, which 
can affect neuronal activity in a relatively chronic and 
consistent manner and allow investigation of the behav-
ioral effects of activation or inhibition of VTA neurons. 
Besides, the AAV has proven to be very effective for study-
ing neuronal function and behavior, it is long-lived, highly 
Fig. 4  Effects of modulation of VTA neurons by DREADD’ activ-
ity during dark period on vigilant states of mice. a–c Hourly amount 
of wakefulness, REM, and NREM sleep after CNO administration 
in the mice microinjected with hSyn-mCherry-AAV10 (n = 6) (a), 
hSyn-hM3Dq-  AAV10 (n = 6) (b), and hSyn- hM4Di-AAV10 (n = 5) 
(c) into the VTA. Each circle represents the hourly mean ± SEM of 
each stage. The horizontal open and filled bars on the x-axes indi-
cate the 12 h light and 12 h dark periods, respectively. d–g In mice 
microinjected with hSyn-hM3Dq-AAV10, examples of polygraphic 
recording and corresponding hypnogram after treatment with saline 
(d) and CNO (e); time spent in each stage in 8 h (21:00–5:00) follow-
ing saline and CNO injection (f); amount and EEG power density of 
NREM sleep in 2 h (5:00–7:00) following CNO-induced arousal (g). 
*p < 0.05, **p < 0.01, assessed by two-tailed paired Student’s t test
◂
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neurotropic, non-pathogenic and, importantly, it can drive 
transgene expression at significantly high levels necessary 
to alter neuronal function and produce a behavioral pheno-
type [24]. In this study, we confirmed its effect by in vitro 
electrophysiological experiments, in which the spontaneous 
firing rates of the hM3Dq-positive neurons were increased 
obviously, while the hM4Di-positive neurons were inhib-
ited by CNO administration. In this way, we can selectively 
manipulate the neurons in the VTA acutely and reversibly.
Considering that the firing activity of DA neurons 
peaked between 07:00 and 11:00 and between 19:00 and 
23:00 [1], we examined the effects of the pharmacogenetic 
activation of the VTA neurons either at 9:00 or at 21:00 
on sleep-wake behaviors in mice. We found no matter the 
level of sleep pressure was high or low [25], and the activa-
tion of VTA produced remarkable increase in wakefulness, 
which lasted longer when CNO was given during the active 
period in mice. The findings demonstrate for the first time 
that injection of CNO in mice expressing hM3Dq in the 
VTA is able to significantly increase arousal. Our results 
were consistent with previous reports that DAT knockout 
mice exhibited an increase in wakefulness [23], selectively 
activating midbrain dopaminergic neurons using DREADD 
induced hyperactivity in DAT-Cre mice [6], and optoge-
netic stimulation of VTA dopaminergic neurons initiated 
and maintained wakefulness in TH-Cre mice [26].
Although the VTA is generally known as the source of 
dopaminergic projection neurons, the VTA contains mul-
tiple cell types: dopaminergic (about 60%); GABAergic 
(about 35%); and glutamatergic neurons (about 5%) [2, 
27]. Therefore, we think that all types of VTA neurons 
were simultaneously activated by this nonspecific phar-
macogenetic DREADD system. VTA DA neurons project 
heavily to several limbic structures, including the nucleus 
accumbens, amygdala, and prefrontal cortex. In the rat, 
both GABAergic and glutamatergic neurons form local 
synapses in the VTA [28, 29] and project in parallel with 
the DA neurons to limbic regions [30, 31]. As a result, the 
increased wakefulness induced by activation of VTA may 
be caused not only by activated dopamine neurons but also 
by glutamatergic neurons. It may increase the dopamine 
and glutamate levels in targeted area which may also con-
tribute to the wakefulness.
It is recognized that sleep is under the control of circa-
dian and homeostatic processes, and animals will attempt to 
regain or compensate for sleep that was previously depleted 
[32, 33]. Previous studies showed that sleep deprivation 
often accompanied with the increase of EEG power density 
of NREM [34, 35]. Our results showed that the activation 
of VTA no matter during the day or night is responsible for 
wakefulness. However, the NREM sleep amount or delta 
power in mice expressing hM3Dq receptors treated with 
CNO following the induced extended wakefulness did not 
increase. The possible reasons may be involved the differ-
ent methods of sleep deprivation, in which gentle handling 
or water platform techniques were employed in the previ-
ous studies, whereas the arousal was induced by VTA acti-
vation using DREADD approach. The present phenomena 
was in agreement with Qiu’s study, in which they did not 
find EEG or behavioral sleep rebound even after 4 days of 
induced wakefulness by chemogenetic stimulation of the 
pontine parabrachial nucleus [36].
To investigate whether the VTA has some roles in 
physiological sleep regulation, the sleep analysis in mice 
with hSyn-hM4Di-AAV10 was carried out. The inhibition 
of VTA neurons was confirmed with patch-clamp record-
ing, in which CNO bath application decreased the firing 
of the mCherry-hM4Di positive neurons. We found there 
were no differences in the mice microinjected with hSyn-
hM4Di-AAV10 between CNO and saline group in sleep-
wake behavior. The reason may be a comprehensive effect 
by inhibition of different type neurons in VTA. When the 
VTA nucleus was inhibited, on one hand, the dopaminergic 
neurons were inhibited; on the other hand, the inhibition 
of the GABAergic neurons could produce disinhibition of 
local dopaminergic neurons. However, we cannot exclude 
some roles of single cell type neurons in VTA in sleep-
wake regulation under physiological conditions. In fact, a 
recent study has shown the VTA dopaminergic neurons are 
necessary for wakefulness since the inhibition of these neu-
rons suppressed wakefulness in TH-Cre mice [26].
In this study, we investigated the role of the VTA in 
sleep/wake regulation; however, viruses indiscriminately 
transduce most cell types within the introduced region. 
Next, we will manipulate neuronal subtypes independently 
to understand the genetic basis of the sleep-wake phenom-
ena for therapeutic purposes.
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